Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 19, 2026

FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile

View original at finance.yahoo.com

FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment* with Wegovy® HD (~19% regardless of whether patie…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Wegovy HD represents an important new tool in obesity management that allows clinicians to better tailor treatment strategies and improve outcomes
60% confidence
Wegovy is the only GLP-1 for adults with obesity proven to reduce the risk of events such as stroke, heart attack, or cardiovascular death in those with known heart disease
60% confidence
The weight loss demonstrated with Wegovy HD could reshape healthcare professionals' expectations about what outcomes are possible for patients with Wegovy
60% confidence
Obesity is a serious, chronic, progressive, and complex disease requiring long-term management, not just a disease of lack of willpower
60% confidence
No other weight loss medicine has been studied to show superiority to Wegovy HD
60% confidence

Data points we hold from this source

Novo Nordisk · pharmacy distribution network	70000 pharmacies
Novo Nordisk · us facilities	10 locations